prednisone and Neuralgia studies

Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.

Neuralgia: Intense or aching pain that occurs along the course or distribution of a peripheral or cranial nerve.

Research Excerpts

Excerpt	Relevance	Reference
"The effects of prednisone, oral acyclovir, and radiotherapy were compared with placebo in the prevention of post-herpetic neuralgia."	9.07	Prevention of post-herpetic neuralgia. Evaluation of treatment with oral prednisone, oral acyclovir, and radiotherapy. ( Allegra, F; Benoldi, D; Mirizzi, S; Zucchi, A, 1991)
" The patients received PTX at the initiating dosage until complete clinical cure."	6.71	[Pentoxifylline in the treatment of erythema nodosum leprosum: results of an open study]. ( Achirafi, A; de Carsalade, GY; Flageul, B, 2003)
"Central poststroke pain is a neuropathic pain syndrome that can occur from pathology of the brain."	5.43	A Medication Combination for the Treatment of Central Poststroke Pain via the Adjuvant Use of Prednisone With Gabapentin: A Case Report. ( Batlle, L; Irwin, R; Mattie, R, 2016)
"The effects of prednisone, oral acyclovir, and radiotherapy were compared with placebo in the prevention of post-herpetic neuralgia."	5.07	Prevention of post-herpetic neuralgia. Evaluation of treatment with oral prednisone, oral acyclovir, and radiotherapy. ( Allegra, F; Benoldi, D; Mirizzi, S; Zucchi, A, 1991)
" We encountered severe autonomic neuropathy and cholestasis in a child receiving vincristine, after the introduction of piperacillin-tazobactam."	3.78	A case of severe toxicity during coadministration of vincristine and piperacillin: are drug transporters involved in vincristine hypersensitivity and drug-drug interactions? ( Andres, CR; Benz-de Bretagne, I; Gendrot, C; Jonville-Bera, AP; Jourdain, A; Le Guellec, C; Tarfaoui, N, 2012)
"Eighty-eight eligible patients with Hodgkin lymphoma stage I and II (<3 nodal sites, no B symptoms, mediastinal bulk, or extranodal extension) enrolled between March 3, 2000, and December 9, 2008."	2.77	Association between radiotherapy vs no radiotherapy based on early response to VAMP chemotherapy and survival among children with favorable-risk Hodgkin lymphoma. ( Billett, AL; Billups, CA; Donaldson, SS; Friedmann, A; Howard, SC; Hudson, MM; Krasin, MJ; Kun, LE; Larsen, EC; Link, MP; Marcus, KJ; Metzger, ML; Tarbell, N; Weinstein, HJ; Wu, J; Yock, TI, 2012)
" The patients received PTX at the initiating dosage until complete clinical cure."	2.71	[Pentoxifylline in the treatment of erythema nodosum leprosum: results of an open study]. ( Achirafi, A; de Carsalade, GY; Flageul, B, 2003)
"Central poststroke pain is a neuropathic pain syndrome that can occur from pathology of the brain."	1.43	A Medication Combination for the Treatment of Central Poststroke Pain via the Adjuvant Use of Prednisone With Gabapentin: A Case Report. ( Batlle, L; Irwin, R; Mattie, R, 2016)
"Although occipital neuralgia is usually caused by degenerative arthropathy, nearly 20 other aetiologies may lead to this condition."	1.42	Idiopathic hypertrophic pachymeningitis presenting with occipital neuralgia. ( Auboire, L; Bienvenu, B; Boutemy, J; Busson, P; Constans, JM; Le Gallou, T, 2015)
"A rare cause of trigeminal neuralgia is malignant lymphoma which spread along the trigeminal nerve."	1.40	[Malignant lymphoma in a perineural spreading along trigeminal nerve, which developed as trigeminal neuralgia]. ( Arakawa, T; Kobayashi, Y; Mano, T; Matsuo, K; Ozawa, H, 2014)
"All patients had acute onset neuropathic pain, normal nerve conduction studies, and evidence of small-fiber dysfunction in quantitative sensory testing and skin biopsy."	1.33	Acute steroid responsive small-fiber sensory neuropathy: a new entity? ( Dabby, R; Gilad, R; Lampl, Y; Sadeh, M; Watemberg, N, 2006)
"Herpes zoster is a common disease which is frequently followed by severe long-term pain--post-herpetic neuralgia."	1.27	Should we treat herpes zoster with corticosteroid agents? ( Dickinson, JA, 1986)

Research

Studies (28)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Correlation of Agreement Between Patient Cognitive Problems (Child + Teen) QoL and Parent Proxy Cognitive Problems (Child + Teen) QoL at Multiple Time Points.

Timeframe	Studies, this research(%)	All Research%
pre-1990	15 (53.57)	18.7374
1990's	2 (7.14)	18.2507
2000's	4 (14.29)	29.6817
2010's	7 (25.00)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Oerlemans, S	1
Issa, DE	1
van den Broek, EC	1
Nijziel, MR	1
Coebergh, JW	1
Huijgens, PC	1
Mols, F	1
van de Poll-Franse, LV	1
Mano, T	1
Matsuo, K	1
Kobayashi, Y	2
Ozawa, H	1
Arakawa, T	1
Auboire, L	1
Boutemy, J	1
Constans, JM	1
Le Gallou, T	1
Busson, P	1
Bienvenu, B	1
Batlle, L	1
Mattie, R	1
Irwin, R	1
Le Guellec, C	1
Benz-de Bretagne, I	1
Jonville-Bera, AP	1
Tarfaoui, N	1
Andres, CR	1
Gendrot, C	1
Jourdain, A	1
Metzger, ML	1
Weinstein, HJ	1
Hudson, MM	1
Billett, AL	1
Larsen, EC	1
Friedmann, A	1
Howard, SC	1
Donaldson, SS	1
Krasin, MJ	1
Kun, LE	1
Marcus, KJ	1
Yock, TI	1
Tarbell, N	1
Billups, CA	1
Wu, J	1
Link, MP	1
Nizeica, V	1
Collet, P	1
Marotte, H	1
Lagalla, G	1
Logullo, F	1
Di Bella, P	1
Provinciali, L	1
Ceravolo, MG	1
ELLIOTT, FA	1
de Carsalade, GY	1
Achirafi, A	1
Flageul, B	1
Dabby, R	1
Gilad, R	1
Sadeh, M	1
Lampl, Y	1
Watemberg, N	1
Gorson, KC	1
Herrmann, DN	1
Thiagarajan, R	1
Brannagan, TH	1
Chin, RL	1
Kinsella, LJ	1
Ropper, AH	1
Clemmensen, OJ	1
Andersen, KE	1
Parkes, JD	1
Calza, AM	1
Schmied, E	1
Harms, M	1
Benoldi, D	1
Mirizzi, S	1
Zucchi, A	1
Allegra, F	1
Anderson, DJ	1
Janoff, EN	1
Diamond, S	1
Dickinson, JA	1
D'Elia, A	1
Colella, C	1
Contursi, R	1
Pearce, J	1
Kronschnabel, EF	1
Saccabusi, E	1
Burch, GE	1
Giles, TD	1
Reifenberg, E	1
Fleischer, K	1
Wieczorek, V	1
Jung, H	1
Leng-Lévy, J	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Risk-Adapted Therapy for Pediatric Hodgkin's Disease[NCT00145600]	Phase 2	296 participants (Actual)	Interventional	2000-03-02	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Assess and compare the patient reported and parent proxy cognitive problems (child + teen) quality of life across multiple time points using the Peds Quality of Life version 3. Assessment was performed across all risk groups. The QL scoring is a 5-point Likert scale from 0 (never) to 4 (almost always). Scores are transformed on a scale from 0 to 100. Items are reverse scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, and 4=0. Total score is the sum of all items over the number of items answered on all scales. The higher the score, the better the quality of life. (NCT00145600)
Timeframe: At completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), and 3-6 months after the completion of therapy (T5)

Correlation of Agreement Between Patient Communication QoL and Parent Proxy Communication QoL at Multiple Time Points.

Intervention	units on a scale (Mean)
Patient Completion of 2 Cycles of Chemotherapy (T2)	77.6
Parent Completion of 2 Cycles of Chemotherapy (T2)	75.7
Patient Completion of 4 Cycles of Chemotherapy (T3)	78.9
Parent Completion of 4 Cycles of Chemotherapy (T3)	74.3
Patient 3-6 Months After the Completion of Therapy (T5)	80.8
Parent 3-6 Months After the Completion of Therapy (T5)	76.3

Assess and compare the patient reported and parent proxy communication quality of life across multiple time points using the Peds Quality of Life version 3. Assessment was performed across all risk groups. The QL scoring is a 5-point Likert scale from 0 (never) to 4 (almost always). Scores are transformed on a scale from 0 to 100. Items are reverse scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, and 4=0. Total score is the sum of all items over the number of items answered on all scales. The higher the score, the better the quality of life. (NCT00145600)
Timeframe: At completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), and 3-6 months after the completion of therapy (T5)

Correlation of Agreement Between Patient Emotional QoL and Parent Proxy Emotional QoL at Multiple Time Points.

Intervention	units on a scale (Mean)
Patient Completion of 2 Cycles of Chemotherapy (T2)	78.3
Parent Completion of 2 Cycles of Chemotherapy (T2)	73.6
Patient Completion of 4 Cycles of Chemotherapy (T3)	80.6
Parent Completion of 4 Cycles of Chemotherapy (T3)	74.9
Patient 3-6 Months After the Completion of Therapy (T5)	83.7
Parent 3-6 Months After the Completion of Therapy (T5)	83.1

Assess and compare the patient reported and parent proxy emotional quality of life across multiple time points using the Peds Quality of Life version 4. Assessment was performed across all risk groups. The QL scoring is a 5-point Likert scale from 0 (never) to 4 (almost always). Scores are transformed on a scale from 0 to 100. Items are reverse scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, and 4=0. Total score is the sum of all items over the number of items answered on all scales. The higher the score, the better the quality of life. (NCT00145600)
Timeframe: At Diagnosis (T1), completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), and 3-6 months after the completion of therapy (T5).

Correlation of Agreement Between Patient Nausea QoL and Parent Proxy Nausea QoL at Multiple Time Points.

Intervention	units on a scale (Mean)
Patient At Diagnosis (T1)	68.4
Parent At Diagnosis (T1)	62.3
Patient Completion of 2 Cycles of Chemotherapy (T2)	70.7
Parent Completion of 2 Cycles of Chemotherapy (T2)	64
Patient Completion of 4 Cycles of Chemotherapy (T3)	74.1
Parent Completion of 4 Cycles of Chemotherapy (T3)	65.7
Patient 3-6 Months After the Completion of Therapy (T5)	78.5
Parent 3-6 Months After the Completion of Therapy (T5)	77.1

Assess and compare the patient reported and parent proxy nausea quality of life across multiple time points using the Peds Quality of Life version 3. Assessment was performed across all risk groups. The QL scoring is a 5-point Likert scale from 0 (never) to 4 (almost always). Scores are transformed on a scale from 0 to 100. Items are reverse scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, and 4=0. Total score is the sum of all items over the number of items answered on all scales. The higher the score, the better the quality of life. (NCT00145600)
Timeframe: At completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), and 3-6 months after the completion of therapy (T5)

Correlation of Agreement Between Patient Pain and Hurt QoL and Parent Proxy Pain and Hurt QoL at Multiple Time Points.

Intervention	units on a scale (Mean)
Patient Completion of 2 Cycles of Chemotherapy (T2)	60.7
Parent Completion of 2 Cycles of Chemotherapy (T2)	58.6
Patient Completion of 4 Cycles of Chemotherapy (T3)	59.7
Parent Completion of 4 Cycles of Chemotherapy (T3)	57.7
Patient 3-6 Months After the Completion of Therapy (T5)	75
Parent 3-6 Months After the Completion of Therapy (T5)	78.9

Assess and compare the patient reported and parent proxy pain and hurt quality of life across multiple time points using the Peds Quality of Life version 3. Assessment was performed across all risk groups. The QL scoring is a 5-point Likert scale from 0 (never) to 4 (almost always). Scores are transformed on a scale from 0 to 100. Items are reverse scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, and 4=0. Total score is the sum of all items over the number of items answered on all scales. The higher the score, the better the quality of life. (NCT00145600)
Timeframe: At completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), and 3-6 months after the completion of therapy (T5).

Correlation of Agreement Between Patient Peds QL4 (Composite) QoL and Parent Proxy Peds QL4 (Composite) QoL at Multiple Time Points.

Intervention	units on a scale (Mean)
Patient Completion of 2 Cycles of Chemotherapy (T2)	67.7
Parent Completion of 2 Cycles of Chemotherapy (T2)	57.3
Patient Completion of 4 Cycles of Chemotherapy (T3)	69.4
Parent Completion of 4 Cycles of Chemotherapy (T3)	60.2
Patient 3-6 Months After the Completion of Therapy (T5)	83.4
Parent 3-6 Months After the Completion of Therapy (T5)	77

Assess and compare the patient reported and parent proxy Peds QL4 (composite) quality of life across multiple time points using the Peds Quality of Life version 4. Assessment was performed across all risk groups. The QL scoring is a 5-point Likert scale from 0 (never) to 4 (almost always). Scores are transformed on a scale from 0 to 100. Items are reverse scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, and 4=0. Total score is the sum of all items over the number of items answered on all scales. The higher the score, the better the quality of life. (NCT00145600)
Timeframe: At Diagnosis (T1), completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), and 3-6 months after the completion of therapy (T5).

Correlation of Agreement Between Patient PedsQL3 (Composite) QoL and Parent Proxy PedsQL3 (Composite) QoL at Multiple Time Points.

Intervention	units on a scale (Mean)
Patient At Diagnosis (T1)	76.2
Parent At Diagnosis (T1)	72.4
Patient Completion of 2 Cycles of Chemotherapy (T2)	74.2
Parent Completion of 2 Cycles of Chemotherapy (T2)	69.3
Patient Completion of 4 Cycles of Chemotherapy (T3)	77
Parent Completion of 4 Cycles of Chemotherapy (T3)	70.6
Patient 3-6 Months After the Completion of Therapy (T5)	84
Parent 3-6 Months After the Completion of Therapy (T5)	80.7

Assess and compare the patient reported and parent proxy PedsQL3 (composite) quality of life across multiple time points using the Peds Quality of Life version 3. Assessment was performed across all risk groups. The QL scoring is a 5-point Likert scale from 0 (never) to 4 (almost always). Scores are transformed on a scale from 0 to 100. Items are reverse scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, and 4=0. Total score is the sum of all items over the number of items answered on all scales. The higher the score, the better the quality of life. (NCT00145600)
Timeframe: At completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), and 3-6 months after the completion of therapy (T5)

Correlation of Agreement Between Patient Perceived Physical Appearance QoL and Parent Proxy Perceived Physical Appearance QoL at Multiple Time Points.

Intervention	units on a scale (Mean)
Patient Completion of 2 Cycles of Chemotherapy (T2)	72.4
Parent Completion of 2 Cycles of Chemotherapy (T2)	68.3
Patient Completion of 4 Cycles of Chemotherapy (T3)	72.7
Parent Completion of 4 Cycles of Chemotherapy (T3)	67.6
Patient 3-6 Months After the Completion of Therapy (T5)	78.1
Parent 3-6 Months After the Completion of Therapy (T5)	77.6

Assess and compare the patient reported and parent proxy perceived physical appearance quality of life across multiple time points using the Peds Quality of Life version 3. Assessment was performed across all risk groups. The QL scoring is a 5-point Likert scale from 0 (never) to 4 (almost always). Scores are transformed on a scale from 0 to 100. Items are reverse scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, and 4=0. Total score is the sum of all items over the number of items answered on all scales. The higher the score, the better the quality of life. (NCT00145600)
Timeframe: At completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), and 3-6 months after the completion of therapy (T5)

Correlation of Agreement Between Patient Physical QoL and Parent Proxy Physical QoL at Multiple Time Points.

Intervention	units on a scale (Mean)
Patient Completion of 2 Cycles of Chemotherapy (T2)	77.5
Parent Completion of 2 Cycles of Chemotherapy (T2)	71.9
Patient Completion of 4 Cycles of Chemotherapy (T3)	77.6
Parent Completion of 4 Cycles of Chemotherapy (T3)	71.2
Patient 3-6 Months After the Completion of Therapy (T5)	78.4
Parent 3-6 Months After the Completion of Therapy (T5)	80.5

Assess and compare the patient reported and parent proxy physical quality of life across multiple time points using the Peds Quality of Life version 4. Assessment was performed across all risk groups. The QL scoring is a 5-point Likert scale from 0 (never) to 4 (almost always). Scores are transformed on a scale from 0 to 100. Items are reverse scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, and 4=0. Total score is the sum of all items over the number of items answered on all scales. The higher the score, the better the quality of life. (NCT00145600)
Timeframe: At Diagnosis (T1), completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), and 3-6 months after the completion of therapy (T5).

Correlation of Agreement Between Patient Procedural Anxiety QoL and Parent Proxy Procedural Anxiety QoL at Multiple Time Points.

Intervention	units on a scale (Mean)
Patient At Diagnosis (T1)	77.2
Parent At Diagnosis (T1)	73.9
Patient Completion of 2 Cycles of Chemotherapy (T2)	72.3
Parent Completion of 2 Cycles of Chemotherapy (T2)	65.4
Patient Completion of 4 Cycles of Chemotherapy (T3)	74.7
Parent Completion of 4 Cycles of Chemotherapy (T3)	66.5
Patient 3-6 Months After the Completion of Therapy (T5)	84.5
Parent 3-6 Months After the Completion of Therapy (T5)	78.6

Assess and compare the patient reported and parent proxy procedural anxiety quality of life across multiple time points using the Peds Quality of Life version 3. Assessment was performed across all risk groups. The QL scoring is a 5-point Likert scale from 0 (never) to 4 (almost always). Scores are transformed on a scale from 0 to 100. Items are reverse scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, and 4=0. Total score is the sum of all items over the number of items answered on all scales. The higher the score, the better the quality of life. (NCT00145600)
Timeframe: At completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), and 3-6 months after the completion of therapy (T5)

Correlation of Agreement Between Patient Psychosocial QoL and Parent Proxy Psychosocial QoL at Multiple Time Points.

Intervention	units on a scale (Mean)
Patient Completion of 2 Cycles of Chemotherapy (T2)	71.3
Parent Completion of 2 Cycles of Chemotherapy (T2)	70.3
Patient Completion of 4 Cycles of Chemotherapy (T3)	73.8
Parent Completion of 4 Cycles of Chemotherapy (T3)	63.2
Patient 3-6 Months After the Completion of Therapy (T5)	78.5
Parent 3-6 Months After the Completion of Therapy (T5)	72.7

Assess and compare the patient reported and parent proxy psychosocial quality of life across multiple time points using the Peds Quality of Life version 4. Assessment was performed across all risk groups. The QL scoring is a 5-point Likert scale from 0 (never) to 4 (almost always). Scores are transformed on a scale from 0 to 100. Items are reverse scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, and 4=0. Total score is the sum of all items over the number of items answered on all scales. The higher the score, the better the quality of life. (NCT00145600)
Timeframe: At Diagnosis (T1), completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), and 3-6 months after the completion of therapy (T5).

Correlation of Agreement Between Patient School QoL and Parent Proxy School QoL at Multiple Time Points.

Intervention	units on a scale (Mean)
Patient At Diagnosis (T1)	75.7
Parent At Diagnosis (T1)	71.3
Patient Completion of 2 Cycles of Chemotherapy (T2)	75.1
Parent Completion of 2 Cycles of Chemotherapy (T2)	71.1
Patient Completion of 4 Cycles of Chemotherapy (T3)	77.5
Parent Completion of 4 Cycles of Chemotherapy (T3)	72.3
Patient 3-6 Months After the Completion of Therapy (T5)	83.1
Parent 3-6 Months After the Completion of Therapy (T5)	80.7

Assess and compare the patient reported and parent proxy school quality of life across multiple time points using the Peds Quality of Life version 4. Assessment was performed across all risk groups. The QL scoring is a 5-point Likert scale from 0 (never) to 4 (almost always). Scores are transformed on a scale from 0 to 100. Items are reverse scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, and 4=0. Total score is the sum of all items over the number of items answered on all scales. The higher the score, the better the quality of life. (NCT00145600)
Timeframe: At Diagnosis (T1), completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), and 3-6 months after the completion of therapy (T5).

Correlation of Agreement Between Patient Social QoL and Parent Proxy Social QoL at Multiple Time Points.

Intervention	units on a scale (Mean)
Patient At Diagnosis (T1)	69.6
Parent At Diagnosis (T1)	66.2
Patient Completion of 2 Cycles of Chemotherapy (T2)	67.2
Parent Completion of 2 Cycles of Chemotherapy (T2)	66.7
Patient Completion of 4 Cycles of Chemotherapy (T3)	69
Parent Completion of 4 Cycles of Chemotherapy (T3)	66.7
Patient 3-6 Months After the Completion of Therapy (T5)	78.6
Parent 3-6 Months After the Completion of Therapy (T5)	76.5

Assess and compare the patient reported and parent proxy social quality of life across multiple time points using the Peds Quality of Life version 4. Assessment was performed across all risk groups. The QL scoring is a 5-point Likert scale from 0 (never) to 4 (almost always). Scores are transformed on a scale from 0 to 100. Items are reverse scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, and 4=0. Total score is the sum of all items over the number of items answered on all scales. The higher the score, the better the quality of life. (NCT00145600)
Timeframe: At Diagnosis (T1), completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), and 3-6 months after the completion of therapy (T5).

Correlation of Agreement Between Patient Treatment Anxiety QoL and Parent Proxy Treatment Anxiety QoL at Multiple Time Points.

Intervention	units on a scale (Mean)
Patient At Diagnosis (T1)	87.2
Parent At Diagnosis (T1)	83
Patient Completion of 2 Cycles of Chemotherapy (T2)	87.2
Parent Completion of 2 Cycles of Chemotherapy (T2)	81.4
Patient Completion of 4 Cycles of Chemotherapy (T3)	88.2
Parent Completion of 4 Cycles of Chemotherapy (T3)	82.2
Patient 3-6 Months After the Completion of Therapy (T5)	91.5
Parent 3-6 Months After the Completion of Therapy (T5)	85.8

Assess and compare the patient reported and parent proxy treatment anxiety quality of life across multiple time points using the Peds Quality of Life version 3. Assessment was performed across all risk groups. The QL scoring is a 5-point Likert scale from 0 (never) to 4 (almost always). Scores are transformed on a scale from 0 to 100. Items are reverse scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, and 4=0. Total score is the sum of all items over the number of items answered on all scales. The higher the score, the better the quality of life. (NCT00145600)
Timeframe: At completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), and 3-6 months after the completion of therapy (T5)

Correlation of Agreement Between Patient Worry QoL and Parent Proxy Worry QoL at Multiple Time Points.

Intervention	units on a scale (Mean)
Patient Completion of 2 Cycles of Chemotherapy (T2)	84.1
Parent Completion of 2 Cycles of Chemotherapy (T2)	72.8
Patient Completion of 4 Cycles of Chemotherapy (T3)	82.8
Parent Completion of 4 Cycles of Chemotherapy (T3)	71.1
Patient 3-6 Months After the Completion of Therapy (T5)	82.1
Parent 3-6 Months After the Completion of Therapy (T5)	77.6

Assess and compare the patient reported and parent proxy worry quality of life across multiple time points using the Peds Quality of Life version 3. Assessment was performed across all risk groups. The QL scoring is a 5-point Likert scale from 0 (never) to 4 (almost always). Scores are transformed on a scale from 0 to 100. Items are reverse scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, and 4=0. Total score is the sum of all items over the number of items answered on all scales. The higher the score, the better the quality of life. (NCT00145600)
Timeframe: At completion of 2 cycles of chemotherapy (T2), completion of 4 cycles of chemotherapy (T3), and 3-6 months after the completion of therapy (T5)

Event-free Survival Probability by Risk Group

Intervention	units on a scale (Mean)
Patient Completion of 2 Cycles of Chemotherapy (T2)	64.5
Parent Completion of 2 Cycles of Chemotherapy (T2)	64.5
Patient Completion of 4 Cycles of Chemotherapy (T3)	64.7
Parent Completion of 4 Cycles of Chemotherapy (T3)	64.7
Patient 3-6 Months After the Completion of Therapy (T5)	67.1
Parent 3-6 Months After the Completion of Therapy (T5)	68.6

Event-free survival (EFS) is based on the time from protocol enrollment to the occurrence of first event (relapse or progressive disease, subsequent malignancy, or death from any cause). Patients not experiencing an event are censored at their last follow-up date. Event-free Survival Probability will be estimated by Kaplan-Meier (KM) method with a 95% confidence interval calculated using the Greenwood's formula. (NCT00145600)
Timeframe: Median 6.4 year follow-up

Event-free Survival Probability by Risk Group at 10-year Follow-Up

Intervention	probability of 5 yr. event free survival (Number)
Favorable Risk	0.886
Intermediate Risk	0.844
Unfavorable Risk, Group 1	0.667
Unfavorable Risk, Group 2	0.793

Event-free survival (EFS) is based on the time from protocol enrollment to the occurrence of first event (relapse or progressive disease, subsequent malignancy, or death from any cause). Patients not experiencing an event are censored at their last follow-up date. Event-free Survival Probability will be estimated by Kaplan-Meier (KM) method with a 95% confidence interval calculated using the with Greenwood's formula. (NCT00145600)
Timeframe: 10-year follow-up after protocol enrollment

Article	Year
Association between radiotherapy vs no radiotherapy based on early response to VAMP chemotherapy and survival among children with favorable-risk Hodgkin lymphoma. JAMA, 2012, Jun-27, Volume: 307, Issue:24 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Disease-Free Su	2012
Influence of early high-dose steroid treatment on Bell's palsy evolution. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2002, Volume: 23, Issue:3 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Bell Palsy; Dose-Response Rela	2002
[Pentoxifylline in the treatment of erythema nodosum leprosum: results of an open study]. Acta leprologica, 2003, Volume: 12, Issue:3 Topics: Adolescent; Adult; Erythema Nodosum; Female; Follow-Up Studies; Glucocorticoids; Humans; Immunosuppr	2003
ACTH versus prednisone and placebo in herpes zoster treatment. Clinical and experimental dermatology, 1984, Volume: 9, Issue:6 Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Cosyntropin; Double-Blind Method; Female; Herpes	1984
Prevention of post-herpetic neuralgia. Evaluation of treatment with oral prednisone, oral acyclovir, and radiotherapy. International journal of dermatology, 1991, Volume: 30, Issue:4 Topics: Acute Disease; Acyclovir; Administration, Oral; Aged; Combined Modality Therapy; Female; Herpes Zost	1991
[Controlled clinical trial a gastroprotective steroid (prednisone + xylamide)]. Minerva medica, 1972, Sep-19, Volume: 63, Issue:65 Topics: Amides; Arthritis, Rheumatoid; Asthma; Benzoates; Bronchitis; Chronic Disease; Drug Combinations; Ev	1972

Article	Year
Health-related quality of life and persistent symptoms in relation to (R-)CHOP14, (R-)CHOP21, and other therapies among patients with diffuse large B-cell lymphoma: results of the population-based PHAROS-registry. Annals of hematology, 2014, Volume: 93, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem	2014
[Malignant lymphoma in a perineural spreading along trigeminal nerve, which developed as trigeminal neuralgia]. Rinsho shinkeigaku = Clinical neurology, 2014, Volume: 54, Issue:8 Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclop	2014
Idiopathic hypertrophic pachymeningitis presenting with occipital neuralgia. African health sciences, 2015, Volume: 15, Issue:1 Topics: Cranial Nerve Diseases; Cyclophosphamide; Dura Mater; Headache; Humans; Immunosuppressive Agents; Ma	2015
A Medication Combination for the Treatment of Central Poststroke Pain via the Adjuvant Use of Prednisone With Gabapentin: A Case Report. PM & R : the journal of injury, function, and rehabilitation, 2016, Volume: 8, Issue:3 Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Drug Thera	2016
A case of severe toxicity during coadministration of vincristine and piperacillin: are drug transporters involved in vincristine hypersensitivity and drug-drug interactions? Journal of pediatric hematology/oncology, 2012, Volume: 34, Issue:8 Topics: Abdominal Pain; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; ATP Binding Cassette T	2012
Bortezomib induced a phrenic palsy in a multiple myeloma patient. Annals of hematology, 2013, Volume: 92, Issue:8 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Boronic Acid	2013
TREATMENT OF HERPES ZOSTER WITH HIGH DOSES OF PREDNISONE. Lancet (London, England), 1964, Sep-19, Volume: 2, Issue:7360 Topics: Geriatrics; Herpes Zoster; Herpes Zoster Ophthalmicus; Humans; Neuralgia; Prednisone; Prognosis	1964
Acute steroid responsive small-fiber sensory neuropathy: a new entity? Journal of the peripheral nervous system : JPNS, 2006, Volume: 11, Issue:1 Topics: Adolescent; Adult; Biopsy; Dermatologic Surgical Procedures; Female; Glucocorticoids; Humans; Immuno	2006
Non-length dependent small fibre neuropathy/ganglionopathy. Journal of neurology, neurosurgery, and psychiatry, 2008, Volume: 79, Issue:2 Topics: Adult; Aged; Autonomic Nervous System; Biopsy; Cell Count; Extremities; Facial Pain; Female; Follow-	2008
Diseases of the central nervous system. Relief of pain: headache, facial neuralgia, migraine, and phantom limb. British medical journal, 1975, Oct-11, Volume: 4, Issue:5988 Topics: Analgesics; Aspirin; Carbamazepine; Ergotamines; Facial Neuralgia; Giant Cell Arteritis; Headache; H	1975
Systemic corticosteroids do not prevent postherpetic neuralgia. Dermatology (Basel, Switzerland), 1992, Volume: 184, Issue:4 Topics: Female; Follow-Up Studies; Herpes Zoster; Humans; Male; Middle Aged; Neuralgia; Prednisone; Random A	1992
Herpes zoster infection in a patient on methotrexate given prednisone to prevent post-herpetic neuralgia. Annals of internal medicine, 1987, Volume: 107, Issue:5 Topics: Aged; Female; Herpes Zoster; Humans; Methotrexate; Neuralgia; Prednisone; Virus Activation	1987
Postherpetic neuralgia. Prevention and treatment. Postgraduate medicine, 1987, Volume: 81, Issue:4 Topics: Aged; Herpes Zoster; Humans; Middle Aged; Nerve Block; Neuralgia; Prednisone; Stellate Ganglion; Tri	1987
Should we treat herpes zoster with corticosteroid agents? The Medical journal of Australia, 1986, Mar-31, Volume: 144, Issue:7 Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Carbamazepine; Child; Child, Preschool; Herpes Zos	1986
Postherpetic neuralgia. British medical journal, 1973, Mar-17, Volume: 1, Issue:5854 Topics: Herpes Zoster; Humans; Neuralgia; Prednisone	1973
Orbital apex syndrome due to sinus infection. The Laryngoscope, 1974, Volume: 84, Issue:3 Topics: Abscess; Anti-Bacterial Agents; Blepharoptosis; Blindness; Cellulitis; Conjunctiva; Cornea; Diagnosi	1974
[Clinical trial of a drug with steroid activity combined with a gastroprotective substance]. Minerva medica, 1972, Sep-08, Volume: 63, Issue:62 Topics: Adult; Amides; Benzoates; Drug Combinations; Drug Tolerance; Gastric Juice; Glutamine; Humans; Infla	1972
Cardiac causalgia. Archives of internal medicine, 1970, Volume: 125, Issue:5 Topics: Adult; Angina Pectoris; Arthritis; Body Temperature; Diagnosis, Differential; Electrocardiography; F	1970
[The cervico-vertebral facial paresis]. Zeitschrift fur arztliche Fortbildung, 1967, May-15, Volume: 61, Issue:10 Topics: Adult; Cervical Vertebrae; Facial Paralysis; Female; Humans; Male; Middle Aged; Neck; Neuralgia; Ost	1967
[On the carotid pain. Giant cell arteritis and Hilger's syndrome]. Zeitschrift fur Laryngologie, Rhinologie, Otologie und ihre Grenzgebiete, 1968, Volume: 47, Issue:3 Topics: Aged; Arteritis; Carotid Artery Diseases; Diagnosis, Differential; Female; Humans; Middle Aged; Migr	1968
[On the clinical picture of the neuralgic amyotrophy (Syndrom of Parsonage and Turner)]. Der Nervenarzt, 1965, Volume: 36, Issue:7 Topics: Adult; Blood Sedimentation; Cerebrospinal Fluid; Electromyography; Female; Humans; Male; Muscular At	1965
[The antalgic and antirheumatic action of a neurotropic vitamin, aspirin and corticoid association]. Semaine therapeutique, 1965, Volume: 41, Issue:9 Topics: Analgesics; Arthritis, Rheumatoid; Aspirin; Humans; Neuralgia; Prednisone; Vitamin B Complex	1965

Intervention	probability 10 yr. event free survival (Number)
Favorable Risk	0.874
Intermediate Risk	0.844
Unfavorable Risk, Group 1	0.667
Unfavorable Risk, Group 2	0.785

prednisone and Neuralgia